Reviewer's report
Title:Osteonecrosis of the jaw in a Crohn's disease patient following a course of
Bisphosphonate and Adalimumab therapy: a case report.
Version: 2Date:20 September 2013
Reviewer: Charles N Bernstein
Reviewer's report:
Major compulsory revisions
This paper needs English language editing.
My problem with this case report is the authors making the connection between
using a bisphosphonate in 2004-2009 and developing osteonecrosis of the jaw in
2013. The authors would need to cite literature from elsewhere that have also
shown markedly delayed osteonecrosis after cessation of bisphosphonate
therapy.
The authors attempt to make the case that anti TNF therapy has exacerbated
this condition but they also gloss over the fact that the patient had “oral” Crohn’s
disease. What type of oral disease? In fact the involved bone had a
granulomatous reaction-so was the bone lesion Crohn’s disease related?
Even if the authors ignore the bisphosphonate use from 5 years previous and
want to report this as a new complication of anti TNF treatment the confounder
remains the oral Crohn's disease
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have consulted to Abbvie Canada maker of Adalimumab
Reviewer's report
Title:Osteonecrosis of the jaw in a Crohn's disease patient following a course of
Bisphosphonate and Adalimumab therapy: a case report.
Version: 2Date:20 September 2013
Reviewer: Charles N Bernstein
Reviewer's report:
Major compulsory revisions
This paper needs English language editing.
My problem with this case report is the authors making the connection between
using a bisphosphonate in 2004-2009 and developing osteonecrosis of the jaw in
2013. The authors would need to cite literature from elsewhere that have also
shown markedly delayed osteonecrosis after cessation of bisphosphonate
therapy.
The authors attempt to make the case that anti TNF therapy has exacerbated
this condition but they also gloss over the fact that the patient had “oral” Crohn’s
disease. What type of oral disease? In fact the involved bone had a
granulomatous reaction-so was the bone lesion Crohn’s disease related?
Even if the authors ignore the bisphosphonate use from 5 years previous and
want to report this as a new complication of anti TNF treatment the confounder
remains the oral Crohn's disease
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have consulted to Abbvie Canada maker of Adalimumab
Please review this paper.
user
Reviewer's report
Title:Osteonecrosis of the jaw in a Crohn's disease patient following a course of
Bisphosphonate and Adalimumab therapy: a case report.
Version: 2Date:20 September 2013
Reviewer: Charles N Bernstein
Reviewer's report:
Major compulsory revisions
This paper needs English language editing.
My problem with this case report is the authors making the connection between
using a bisphosphonate in 2004-2009 and developing osteonecrosis of the jaw in
2013. The authors would need to cite literature from elsewhere that have also
shown markedly delayed osteonecrosis after cessation of bisphosphonate
therapy.
The authors attempt to make the case that anti TNF therapy has exacerbated
this condition but they also gloss over the fact that the patient had “oral” Crohn’s
disease. What type of oral disease? In fact the involved bone had a
granulomatous reaction-so was the bone lesion Crohn’s disease related?
Even if the authors ignore the bisphosphonate use from 5 years previous and
want to report this as a new complication of anti TNF treatment the confounder
remains the oral Crohn's disease
Level of interest: An article of limited interest
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have consulted to Abbvie Canada maker of Adalimumab
assistant